Sinopharm finally publishes Covid-19 vaccine trial data: interim Phase 3 results suggest two products have efficacy rates well above 50 per cent but there is little data on the elderly and other vulnerable groups https://ift.tt/3vxT8xA https://ift.tt/3ia82Gv https://ift.tt/3ia82Gv https://ift.tt/3yM4csE

https://ift.tt/3ia82Gv

Submitted May 27, 2021 at 08:47PM by DoremusJessup https://ift.tt/3yM4csE DoremusJessup